Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19

NCT04405570 is registered in ClinicalTrials.gov with Ridgeback Biotherapeutics, LP as lead sponsor.

NCT NCT04405570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04405570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19
Lead sponsor
Ridgeback Biotherapeutics, LP
Phase
Phase 2
Overall status
Completed
Start date
June 19, 2020
Completion date
February 21, 2021
Enrollment
204 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 infection, covid-19